These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
780 related items for PubMed ID: 19718047
1. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance. Luo W, Gangwal K, Sankar S, Boucher KM, Thomas D, Lessnick SL. Oncogene; 2009 Nov 19; 28(46):4126-32. PubMed ID: 19718047 [Abstract] [Full Text] [Related]
2. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells. García-Aragoncillo E, Carrillo J, Lalli E, Agra N, Gómez-López G, Pestaña A, Alonso J. Oncogene; 2008 Oct 09; 27(46):6034-43. PubMed ID: 18591936 [Abstract] [Full Text] [Related]
3. Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro. Chansky HA, Barahmand-Pour F, Mei Q, Kahn-Farooqi W, Zielinska-Kwiatkowska A, Blackburn M, Chansky K, Conrad EU, Bruckner JD, Greenlee TK, Yang L. J Orthop Res; 2004 Jul 09; 22(4):910-7. PubMed ID: 15183454 [Abstract] [Full Text] [Related]
4. A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells. Girnita L, Girnita A, Wang M, Meis-Kindblom JM, Kindblom LG, Larsson O. Oncogene; 2000 Aug 31; 19(37):4298-301. PubMed ID: 10980604 [Abstract] [Full Text] [Related]
5. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. Lin PP, Brody RI, Hamelin AC, Bradner JE, Healey JH, Ladanyi M. Cancer Res; 1999 Apr 01; 59(7):1428-32. PubMed ID: 10197607 [Abstract] [Full Text] [Related]
6. Preferential down-regulation of phospholipase C-beta in Ewing's sarcoma cells transfected with antisense EWS-Fli-1. Dohjima T, Ohno T, Banno Y, Nozawa Y, Wen-yi Y, Shimizu K. Br J Cancer; 2000 Jan 01; 82(1):16-9. PubMed ID: 10638960 [Abstract] [Full Text] [Related]
7. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Kinsey M, Smith R, Lessnick SL. Mol Cancer Res; 2006 Nov 01; 4(11):851-9. PubMed ID: 17114343 [Abstract] [Full Text] [Related]
8. Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene. Lessnick SL, Braun BS, Denny CT, May WA. Oncogene; 1995 Feb 02; 10(3):423-31. PubMed ID: 7845667 [Abstract] [Full Text] [Related]
9. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors. Castillero-Trejo Y, Eliazer S, Xiang L, Richardson JA, Ilaria RL. Cancer Res; 2005 Oct 01; 65(19):8698-705. PubMed ID: 16204038 [Abstract] [Full Text] [Related]
10. Divergent Ewing's sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells. Thompson AD, Teitell MA, Arvand A, Denny CT. Oncogene; 1999 Sep 30; 18(40):5506-13. PubMed ID: 10523827 [Abstract] [Full Text] [Related]
11. Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing's sarcoma cells. Wang M, Xie Y, Girnita L, Nilsson G, Dricu A, Wejde J, Larsson O. Exp Cell Res; 1999 Jan 10; 246(1):38-46. PubMed ID: 9882513 [Abstract] [Full Text] [Related]
12. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma. Mateo-Lozano S, Gokhale PC, Soldatenkov VA, Dritschilo A, Tirado OM, Notario V. Clin Cancer Res; 2006 Nov 15; 12(22):6781-90. PubMed ID: 17121899 [Abstract] [Full Text] [Related]
13. Transforming activity of EWS/FLI is not strictly dependent upon DNA-binding activity. Jaishankar S, Zhang J, Roussel MF, Baker SJ. Oncogene; 1999 Sep 30; 18(40):5592-7. PubMed ID: 10523836 [Abstract] [Full Text] [Related]
14. EWS/ETS fusions activate telomerase in Ewing's tumors. Takahashi A, Higashino F, Aoyagi M, Yoshida K, Itoh M, Kyo S, Ohno T, Taira T, Ariga H, Nakajima K, Hatta M, Kobayashi M, Sano H, Kohgo T, Shindoh M. Cancer Res; 2003 Dec 01; 63(23):8338-44. PubMed ID: 14678994 [Abstract] [Full Text] [Related]
15. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y. J Clin Invest; 1997 Jan 15; 99(2):239-47. PubMed ID: 9005992 [Abstract] [Full Text] [Related]
16. Induction of tenascin-C by tumor-specific EWS-ETS fusion genes. Watanabe G, Nishimori H, Irifune H, Sasaki Y, Ishida S, Zembutsu H, Tanaka T, Kawaguchi S, Wada T, Hata J, Kusakabe M, Yoshida K, Nakamura Y, Tokino T. Genes Chromosomes Cancer; 2003 Mar 15; 36(3):224-32. PubMed ID: 12557222 [Abstract] [Full Text] [Related]
17. Differential regulation of the response to DNA damage in Ewing's sarcoma cells by ETS1 and EWS/FLI-1. Soldatenkov VA, Trofimova IN, Rouzaut A, McDermott F, Dritschilo A, Notario V. Oncogene; 2002 Apr 25; 21(18):2890-5. PubMed ID: 11973649 [Abstract] [Full Text] [Related]
18. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Ouchida M, Ohno T, Fujimura Y, Rao VN, Reddy ES. Oncogene; 1995 Sep 21; 11(6):1049-54. PubMed ID: 7566963 [Abstract] [Full Text] [Related]
19. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. Nat Genet; 1994 Feb 21; 6(2):146-51. PubMed ID: 8162068 [Abstract] [Full Text] [Related]
20. Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias. Yi H, Fujimura Y, Ouchida M, Prasad DD, Rao VN, Reddy ES. Oncogene; 1997 Mar 20; 14(11):1259-68. PubMed ID: 9178886 [Abstract] [Full Text] [Related] Page: [Next] [New Search]